The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

Inclusion Criteria: * Both males and females will be enrolled and must be at least 18 years of age and under age of 90 * Patients, who in the opinion of the Investigator, require biopsy to rule out PDAC because they display at least one of the following or both: a) clinical symptoms of PDAC including jaundice, nausea and vomiting, weight loss, abdominal pain, bloating or the feeling of fullness, itchy skin, lower back pain, light-colored, greasy stools, sudden onset type 2 diabetes, etc. b) one or more imaging studies suggestive of PDAC * All patients must undergo contemporaneous imaging, either within 90 days before the LINFU® procedure or within 30 days after the procedure, with one or more of the following: EUS± FNA, MRI/MRCP, ERCP, CT or CEUS. * Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study. Exclusion Criteria: * Patient under the age of 18 and over the age 90 * Contraindications to LINFU®/EUS/ERCP as determined by study investigators: Patient with uncorrectable coagulopathy; Patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist; Unstable medically (cardiopulmonary, neurologic, or cardiovascular status) * Patients undergoing EUS or ERCP for a suspected bile duct cancer arising from the intrahepatic or extrahepatic biliary epithelium * Patients who are already known to have PDAC by cytologic or histologic evidence * Patients with intraductal papillary mucinous neoplasm of the pancreas (IPMN) identified either before the study or during the study through imaging evaluation will be excluded * Pregnant females will be excluded * Patient that is unable to provide informed consent * Patient with known allergy to the microbubble contrast agent or secretin